Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels

Archives of Neurology

Volumn 68, Issue 5, 2011, Pages 581-586

  Cruchaga, Carlos ^a   Graff, Caroline ^b,c   Chiang, Huei Hsin ^b   Wang, Jun ^a   Hinrichs, Anthony L ^a   Spiegel, Noah ^a   Bertelsen, Sarah ^a   Mayo, Kevin ^a   Norton, Joanne B ^a   Morris, John C ^a   Goate, Alison ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULIN; PROGRANULIN; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILY STUDY; FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL LOBAR DEGENERATION WITH TAR DNA BINDING PROTEIN INCLUSION; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE MAP; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATION CARRIER; NEUROPATHOLOGY; ONSET AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TMEM106B GENE;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LINKAGE DISEQUILIBRIUM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SERINE; THREONINE; TIME FACTORS;

EID: 79955748378     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.350     Document Type: Article

References (36)

1. Seshadri S, Fitzpatrick AL, Ikram MA, et al; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832-1840.
2. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088-1093.
3. Lambert JC, Heath S, Even G, et al; European Alzheimer's Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094- 1099.
4. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74(2):97-109.
5. Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42(3):234-239.
6. Arvanitakis Z. Update on frontotemporal dementia. Neurologist. 2010;16(1):16-22.
7. Behrens MI, Mukherjee O, Tu PH, et al. Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. Alzheimer Dis Assoc Disord. 2007;21(1):1-7. (Pubitemid 46398949)
8. Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006; 15(20):2988-3001. (Pubitemid 44530703)
9. Mukherjee O, Pastor P, Cairns NJ, et al. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by amissense mutation in the signal peptide of progranulin. Ann Neurol. 2006;60(3):314-322. (Pubitemid 44520234)
10. Chiang HH, Rosvall L, Brohede J, et al. Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family. Alzheimers Dement. 2008;4(6):414-420.
11. Carecchio M, Fenoglio C, De Riz M, et al. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers: a case with atypical onset as clinical amnestic mild cognitive impairment converted to Alzheimer's disease. J Neurol Sci. 2009;287(1-2):291-293.
12. Bird TD. Progranulin plasma levels in the diagnosis of frontotemporal dementia. Brain. 2009;132(pt 3):568-569.
13. Finch N, Baker M, Crook R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132(pt 3):583-591.
14. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414. (Pubitemid 23346995)
15. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479-486.
16. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques. 2002;32(6):1372-1374, 1376, 1378-1379.
17. Myers AJ, Gibbs JR, Webster JA, et al. A survey of genetic human cortical gene expression. Nat Genet. 2007;39(12):1494-1499. (Pubitemid 350191339)
18. Zhao H. Family-based association studies. Stat Methods Med Res. 2000;9(6):563-587. (Pubitemid 32229170)
19. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998;19(4):357-360. (Pubitemid 28357907)
20. Siegmund KD, Langholz B, Kraft P, Thomas DC. Testing linkage disequilibrium in sibships. Am J Hum Genet. 2000;67(1):244-248. (Pubitemid 30481563)
21. Kraft P, Thomas DC. Case-sibling gene-association studies for diseases with variable age at onset. Stat Med. 2004;23(23):3697-3712. (Pubitemid 39549572)
22. Romas SN, Mayeux R, Tang MX, et al. No association between a presenilin 1 polymorphism and Alzheimer disease. Arch Neurol. 2000;57(5):699-702.
23. Rademakers R, Baker M, Gass J, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C - >T (Arg493X) mutation: an international initiative. Lancet Neurol. 2007;6(10):857-868. (Pubitemid 47404986)
24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265. (Pubitemid 40202029)
25. Conde L, Vaquerizas JM, Dopazo H, et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res. 2006;34(web server issue):W621-5.
26. Mukherjee O, Wang J, Gitcho M, et al. Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat. 2008;29(4):512-521. (Pubitemid 351536990)
27. Goñi JR, de la Cruz X, Orozco M. Triplex-forming oligonucleotide target sequences in the human genome. Nucleic Acids Res. 2004;32(1):354-360. (Pubitemid 38228635)
28. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
29. Sleegers K, Brouwers N, Van Damme P, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65(5):603-609.
30. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71(16):1235-1239.
31. Pastor P, Roe CM, Villegas A, et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54(2):163-169. (Pubitemid 36909615)
32. Kauwe JS, Cruchaga C, Bertelsen S, et al; Alzheimer's Disease Neuroimaging Initiative. Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J Alzheimers Dis. 2010;21(3):833-842.
33. Kauwe JS, Cruchaga C, Mayo K, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008;105(23):8050-8054. (Pubitemid 351904706)
34. Kauwe JS, Wang J, Mayo K, et al. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics. 2009;10(1):13-17.
35. Cruchaga C, Kauwe JS, Mayo K, et al; Alzheimer's Disease Neuroimaging Initiative. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet. 2010;6(9):pii: e1001101.
36. Langbehn DR, Hayden MR, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):397-408.